CMV Renal Effects
Cytomegalovirus (CMV) can cause direct renal parenchymal infection manifesting as glomerulopathy or tubulointerstitial nephritis, and should be suspected in any transplant recipient with unexplained rise in serum creatinine, even if asymptomatic.
Renal Manifestations of CMV
CMV affects the kidney through two primary mechanisms:
Direct Renal Infection
- Glomerulopathy (most common renal manifestation) 1
- Tubulointerstitial involvement with tubular necrosis 1
- Presents with acute kidney injury and rising creatinine 2, 3
- Biopsy shows CMV inclusion bodies in renal tissue 1, 4
Clinical Presentation
72% of kidney transplant recipients with CMV infection have serum creatinine above baseline 2. The key clinical features include:
- Asymptomatic creatinine elevation (20-67% present without symptoms) 2, 3
- Low-grade fever (16-65% of cases) 2, 3
- Diarrhea (15-20%) 2, 3
- Abdominal pain (21%) 2
Laboratory Abnormalities
- Lymphopenia (46% of patients) 3
- Anemia (40-64%) 2, 3
- Thrombocytopenia (14-47%) 2, 3
- Elevated transaminases (18%) 3
Important caveat: CMV viremia may be detectable in only 5 out of 6 cases of biopsy-proven renal CMV infection, meaning negative viremia does not exclude renal involvement 1.
Treatment Recommendations
For Serious/Tissue-Invasive CMV Disease (Including Renal Involvement)
All patients with serious CMV disease, including tissue-invasive renal infection, must be treated with intravenous ganciclovir 5.
Treatment algorithm:
Initiate IV ganciclovir 5 mg/kg every 12 hours (adjusted for renal function) 5, 6
Monitor weekly with CMV NAT (PCR) or pp65 antigenemia 5
Continue therapy until CMV is no longer detectable by plasma NAT or pp65 antigenemia 5
Reduce immunosuppression in life-threatening CMV disease or disease persisting despite treatment 5
Monitor graft function closely during CMV disease 5
For Mild CMV Disease in Adults
If CMV disease is not serious (mild clinical symptoms without tissue invasion), either IV ganciclovir or oral valganciclovir may be used 5.
For Pediatric Patients
All CMV disease in pediatric kidney transplant recipients must be treated with IV ganciclovir regardless of severity 5.
Alternative Agents
- Foscarnet: Use when ganciclovir causes myelosuppression or in ganciclovir-resistant CMV 6
- Maribavir: For resistant or refractory CMV infection after first-line therapy failure 7, 8, 9
- Cidofovir: Reserved for resistant cases due to significant nephrotoxicity risk 6
Treatment Outcomes
Renal function improves in approximately 67% of patients following successful CMV treatment 1. Studies show significant improvement in kidney and liver functions after successful treatment 3. However, 42% of treated patients experience CMV recurrence 2, necessitating continued surveillance.
Critical Pitfalls to Avoid
Do not wait for symptoms - 20-67% of patients with CMV renal infection are asymptomatic 2, 3
Do not rely solely on viremia - Renal CMV infection can occur with negative blood CMV PCR 1
Do not use oral valganciclovir for serious disease - Tissue-invasive disease requires IV ganciclovir 5, 6
Do not stop treatment prematurely - Continue until CMV is undetectable, not just until symptoms resolve 5
Do not ignore rising creatinine - Any unexplained creatinine elevation in a transplant recipient warrants CMV evaluation 2, 3